Helicobacter pylori infection and Peptic ulcers

Deep Dive

From a western clinical standpoint, Helicobacter pylori infection is the dominant infectious driver of peptic ulcer disease (PUD). The organism’... From a western clinical standpoint, Helicobacter pylori infection is the dominant infectious driver of peptic ulcer disease (PUD). The organism’s urease activity neutralizes gastric acid at the mucosal surface, while flagella and adhesins allow penetration into the mucus layer. Virulence factors such as CagA and VacA, coupled with the host inflammatory response, erode epithelial defenses and alter acid regulation. Antral-predominant gastritis reduces somatostatin and increases gastrin, leading to acid hypersecretion that promotes duodenal gastric metaplasia and ulceration. Corpus-predominant gastritis can suppress acid and foster atrophic changes, with different clinical implications. Although ulcers also occur with NSAIDs/aspirin, critical illness, and rare hypersecretory states (e.g., Zollinger–Ellison syndrome), the intersection of H. pylori with NSAIDs is especially consequential: together they multiply the risk of ulcers and bleeding. Diagnosis follows a risk-stratified approach. In patients younger than about 55–60 without alarm features, noninvasive tests—13C urea breath test or monoclonal stool antigen—accurately detect infection. Endoscopy with biopsy (rapid urease testing, histology, and culture where available) is preferred with red flags, in older adults with new dyspepsia, or when gastric ulcers are suspected, both to diagnose and to exclude malignancy. Because PPIs, bismuth, and antibiotics can suppress the organism, they are withheld before testing when safe. Rising antibiotic resistance has shifted first-line therapy toward bismuth-containing quadruple regimens or non-bismuth concomitant combinations, tailored where possible to local resistance patterns or susceptibility testing. Confirmation of eradication—by breath or stool antigen testing at least four weeks after antibiotics and two weeks off PPIs—is recommended. Clinically, eradication plus acid suppression heals most ulcers and prevents relapse and bleeding. In complicated ulcers (e.g., bleeding), endoscopic hemostasis combined with high-dose PPI therapy reduces rebleeding. Preventive strategies include testing for and treating H. pylori before initiating long-term NSAIDs, minimizing NSAID exposure, smoking cessation, and addressing comorbid risks. The long-term outlook after successful eradication is excellent, with low reinfection rates in low-prevalence settings and meaningful reductions in gastric cancer risk.